Top-Rated StocksTop-RatedNASDAQ:ONC BeOne Medicines (ONC) Stock Price, News & Analysis $390.94 -8.76 (-2.19%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$390.72 -0.21 (-0.05%) As of 11/20/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BeOne Medicines Stock (NASDAQ:ONC) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BeOne Medicines alerts:Sign Up Key Stats Today's Range$385.00▼$399.7650-Day Range$346.50▼$424.0052-Week Range$253.95▼$424.73Volume356,778 shsAverage Volume460,593 shsMarket Capitalization$42.92 billionP/E Ratio49.67Dividend YieldN/APrice Target$441.64Consensus RatingBuy Company Overview BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer. BeOne also develops additional oncology treatments through a broad research and clinical development pipeline. Co-founder John V. Oyler serves as the company’s chairman and chief executive officer.AI Generated. May Contain Errors. Read More BeOne Medicines Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks82nd Percentile Overall ScoreONC MarketRank™: 4.09708737864 of 5 starsBeOne Medicines scored higher than 82% of companies evaluated by MarketBeat, and ranked 124th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingBeOne Medicines has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 16 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBeOne Medicines has a consensus price target of $441.64, representing about 13.0% upside from its current price of $390.94.Amount of Analyst CoverageBeOne Medicines has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BeOne Medicines' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth40.58% Earnings GrowthEarnings for BeOne Medicines are expected to grow by 40.58% in the coming year, from $9.98 to $14.03 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BeOne Medicines is 49.67, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.26.Price to Earnings Ratio vs. SectorThe P/E ratio of BeOne Medicines is 49.67, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.53.Price to Book Value per Share RatioBeOne Medicines has a P/B Ratio of 7.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.56% of the float of BeOne Medicines has been sold short.Short Interest Ratio / Days to CoverBeOne Medicines has a short interest ratio ("days to cover") of 4.37.Change versus previous monthShort interest in BeOne Medicines has recently decreased by 10.61%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBeOne Medicines does not currently pay a dividend.Dividend GrowthBeOne Medicines does not have a long track record of dividend growth. News and Social Media4.2 / 5News Sentiment0.74 News SentimentBeOne Medicines has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.41 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for BeOne Medicines this week, compared to 6 articles on an average week.Search Interest8 people have searched for ONC on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows5 people have added BeOne Medicines to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BeOne Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $48,487,792.00 in company stock.Percentage Held by Insiders6.19% of the stock of BeOne Medicines is held by insiders.Percentage Held by Institutions48.55% of the stock of BeOne Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BeOne Medicines' insider trading history. Receive ONC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BeOne Medicines and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ONC Stock News HeadlinesAnalysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), BeOne Medicines (ONC)November 21 at 12:42 PM | theglobeandmail.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) StockNovember 21 at 2:12 AM | americanbankingnews.com$0. Later: $29.97.Bill Poulos is giving away his Simple Options Trading For Beginners book through a temporary link. Once that link expires, it returns to its usual price of $29.97. The content stays the same - plain-English lessons and a handful of proven techniques - only the price changes. Waiting means paying for something you could have gotten for free.November 21 at 1:00 AM | Profits Run (Ad)Up 15% since October: Inside the oncology stock beating healthcareNovember 19 at 8:49 AM | uk.finance.yahoo.comCLL Society and BeOne Medicines Announce Expanded Partnership to Advance Education and Support Across the CLL/SLL CommunityNovember 17, 2026 | marketscreener.comMBeOne Medicines (NASDAQ:ONC) Insider Sells $632,283.63 in StockNovember 11, 2026 | insidertrades.comBeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 1,115 Shares of Company StockNovember 10, 2026 | insidertrades.comInsider Selling: BeOne Medicines (NASDAQ:ONC) Insider Sells $11,262,233.16 in StockOctober 30, 2026 | insidertrades.comSee More Headlines ONC Stock Analysis - Frequently Asked Questions How have ONC shares performed this year? BeOne Medicines' stock was trading at $303.81 at the beginning of the year. Since then, ONC shares have increased by 28.7% and is now trading at $390.94. How were BeOne Medicines' earnings last quarter? BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) issued its earnings results on Thursday, November, 5th. The company reported $3.64 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.34 by $1.30. The firm had revenue of $1.89 billion for the quarter, compared to analysts' expectations of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a trailing twelve-month return on equity of 19.04%. Read the conference call transcript. When did BeOne Medicines IPO? BeOne Medicines (ONC) raised $152 million in an IPO on Wednesday, February 3rd 2016. The company issued 6,600,000 shares at $22.00-$24.00 per share. Who are BeOne Medicines' major shareholders? BeOne Medicines' top institutional investors include Baker BROS. Advisors LP (8.04%), First Trust Advisors LP (0.29%), Candriam S.C.A. (0.26%) and Goldman Sachs Group Inc. (0.18%). Insiders that own company stock include Bros Advisors Lp Baker, John Oyler, Xiaodong Wang, Titus B Ball, Chan Henry Lee, Xiaobin Wu, Margaret Dugan, Lai Wang, Lai Wang, Corazon (Corsee) D Sanders, Corazon (Corsee) D Sanders, Alessandro Riva and Aaron Rosenberg. View institutional ownership trends. How do I buy shares of BeOne Medicines? Shares of ONC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BeOne Medicines own? Based on aggregate information from My MarketBeat watchlists, some other companies that BeOne Medicines investors own include NVIDIA (NVDA), Micron Technology (MU), Bloom Energy (BE), Citigroup (C), Celestica (CLS), Coherent (COHR) and Arista Networks (ANET). Company Calendar Last Earnings11/05/2026Today11/21/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (4m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ONC's financial health is in the Green zone, according to TradeSmith. ONC has been in this zone for over 4 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:ONC Previous SymbolNASDAQ:ONC CIK1651308 Webbeonemedicines.com Phone13459494123FaxN/AEmployees12,000Year FoundedN/APrice Target and Rating Average Price Target for BeOne Medicines$441.64 High Price Target$484.91 Low Price Target$367.00 Potential Upside/Downside+13.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)$7.87 Trailing P/E Ratio49.67 Forward P/E Ratio27.86 P/E GrowthN/ANet Income$286.93 million Net Margins13.86% Pretax Margin17.12% Return on Equity19.04% Return on Assets10.70% Debt Debt-to-Equity Ratio0.14 Current Ratio3.55 Quick Ratio3.19 Sales & Book Value Annual Sales$5.34 billion Price / Sales8.03 Cash Flow$3.72 per share Price / Cash Flow105.23 Book Value$53.01 per share Price / Book7.37Miscellaneous Outstanding Shares109,790,000Free Float102,991,000Market Cap$42.92 billion OptionableOptionable Beta0.63 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ONC) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersPrediction: NVDA will “snap back” on this dateOthers paid $500 for the Snapback Indicator. For Black Friday, Base Camp Trading is offering lifetime access f...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredAre Tesla and SpaceX Going Bankrupt?Tesla and SpaceX shares crashed right after Democrats took the House and the Senate in the midterm election. E...Brownstone Research | Sponsored432 miles southeast of Washington, DC…Spruce Pine, North Carolina, a town of just over 2,000 people, has supplied a material to every major chip mak...Wall Street Watchdogs | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeOne Medicines Ltd. - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BeOne Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.